M^pro^

:   main protease

SARS‐CoV‐2

:   severe acute respiratory syndrome coronavirus 2

A novel coronavirus (severe acute respiratory syndrome coronavirus 2 \[SARS‐CoV‐2\], or 2019 novel coronavirus \[2019‐nCoV\]) has been identified as the pathogen of coronavirus disease 2019. The coronavirus has spread worldwide and exhibits strong contagious and infective characteristics. There are no effective anti‐SARS‐CoV‐2 drugs at the time of writing. The discovery of potential anti‐SARS‐CoV‐2 drugs from known drug libraries is thought to be an effective drug repositioning strategy for shortening the clinical development period.

Severe acute respiratory syndrome coronavirus 2 belongs to the betacoronavirus group. One of the best‐characterized drug targets among viral constituents is the main protease (M^pro^, also called 3‐chymotrypsin‐like protease) \[[1](#feb412875-bib-0001){ref-type="ref"}\]. Crystal structures of the M^pro^ dimer, the biological active form, have been resolved with or without synthetic inhibitors, some of which covalently bind to Cys145 at the catalytic dyad (i.e., Cys145 and His41) or have been designed to covalently bind to Cys145 (Fig. [1](#feb412875-fig-0001){ref-type="fig"}) \[[2](#feb412875-bib-0002){ref-type="ref"}, [3](#feb412875-bib-0003){ref-type="ref"}\]. However, side effects, toxicity, and lower potency often cause covalent inhibitors to drop out. Therefore, noncovalent inhibitors with high binding affinity are more suited for treatment of such viral infections.

![Refined crystal structure (PDB ID: <https://doi.org/10.2210/pdb6Y2G/pdb>) of a SARS‐CoV‐2 M^pro^ homodimer with peptidomimetic α‐ketoamide inhibitors. (A) Whole structure and (B) enlarged structure of the active site. Chains A and B of the M^pro^ homodimer are shown as red and cyan ribbons, respectively. Peptidomimetic α‐ketoamide inhibitors are shown in CPK color using space‐filling models. Water molecules are shown using tubes. Residues located 3 Å from the inhibitors are shown in CPK color using tubes without nonpolar hydrogen atoms. Van der Waals surfaces of the active sites are shown in gray.](FEB4-10-995-g001){#feb412875-fig-0001}

In this study, I performed stepwise structure‐based virtual screenings using two different docking simulations in order to discover potential drugs that target M^pro^ using the ChEMBL database \[[4](#feb412875-bib-0004){ref-type="ref"}\], which mainly lists drugs and known bioactive compounds. I present these potential anti‐SARS‐CoV‐2 drug candidates here. The structural information of the potential drugs will be useful for improving their pharmacokinetic properties more effectively and for developing specific anti‐SARS‐CoV‐2 drugs.

Methods {#feb412875-sec-0002}
=======

Refinement of the M^pro^ crystal structure {#feb412875-sec-0003}
------------------------------------------

I prepared the M^pro^ homodimer structure suitable for docking simulations using a crystal structure (PDB ID: <https://doi.org/10.2210/pdb6Y2G/pdb> \[[2](#feb412875-bib-0002){ref-type="ref"}\]; resolution 2.20 Å). Structural refinement was performed using Homology Modeling Professional for [hyperchem]{.smallcaps} (HMHC) software \[[5](#feb412875-bib-0005){ref-type="ref"}, [6](#feb412875-bib-0006){ref-type="ref"}\], and energy calculations were performed under the AMBER99 force field with the following parameters: root‐mean‐square gradient, 1.0 kcal·mol^−1^·Å^−1^; algorithm, Polak--Ribière; cutoffs, none; 1--4 van der Waals scale factor, 0.5; 1--4 electrostatic scale factor, 0.833; dielectric scale factor, 1.0; and distance‐dependent dielectric condition. Structural refinement was conducted in the presence of peptidomimetic α‐ketoamide inhibitors, which were previously disconnected from each Cys145 of the M^pro^ homodimer. After adding hydrogen atoms automatically, I assigned Mulliken atomic charges of inhibitors; their α‐carbonyl moiety (disconnected from Cys145) was treated as a hydroxy carbocation using single‐point calculations of the semiempirical MNDO/d method. Mulliken atomic charges obtained from the MNDO/d calculation showed empirically good correlation with AMBER charges \[[7](#feb412875-bib-0007){ref-type="ref"}\]. In addition, AMBER99 atom types were assigned. N‐ and C‐terminals of the M^pro^ homodimer were treated as zwitterions, aspartic and glutamic acid residues were treated as anions, while lysine, arginine, and histidine residues were treated as cations under physiological conditions. Next, a free glycine included in the crystal structure was removed, and the initial coordinates of hydrogen atoms of crystal waters (one water, WAT620, was removed, since the initial coordinate of the hydrogen atoms could not be assigned) were predicted using HMHC. Subsequently, partial optimization by Belly calculations for all components, except heavy atoms, was performed, and distance restraint conditions (7.0 kcal·mol^−1^·Å^−2^) were applied to all heavy atoms of the above structure; next, geometry optimization calculations were performed. The resulting structure was subjected to low‐temperature molecular dynamics annealing (starting temperature 0 K; heat time 30 ps; simulation temperature 300 K; run time 100 ps; final temperature 0 K; cooling time 30 ps; step size 0.001 ps; and temperature step 0.01 K). Finally, all distance restraint conditions were removed, and the structure was further optimized to obtain the final structure. Precision of the final structure was confirmed using a Ramachandran plot program of HMHC.

Preparation of 3D structures from the ChEMBL database {#feb412875-sec-0004}
-----------------------------------------------------

Planar structures of the ChEMBL database (ChEMBL26; 1 950 760 distinct compounds, including 13 308 drugs) \[[4](#feb412875-bib-0004){ref-type="ref"}\] were downloaded from the ChEMBL website in SDF file format. MayaChemTools (2019) \[[8](#feb412875-bib-0008){ref-type="ref"}\] was used to remove counterions and inorganic compounds from the database. Then, 3D structures were obtained using [balloon]{.smallcaps} version 1.6.9 \[[9](#feb412875-bib-0009){ref-type="ref"}\] under an MMFF94 force field. The resulting 3D structure database was treated using [babel]{.smallcaps} version 2.4.1 \[[10](#feb412875-bib-0010){ref-type="ref"}\]; the compounds' protonation state was prepared under physiological conditions (pH = 7.4) and filtered by molecular weight (MW ≥ 100 and ≤ 500) to reduce the database to a more drug‐like library. A total of 1 485 144 compounds were used for subsequent virtual screenings.

Structure‐based virtual screenings {#feb412875-sec-0005}
----------------------------------

Structure‐based virtual screenings were performed using [rdock]{.smallcaps} (2013) \[[11](#feb412875-bib-0011){ref-type="ref"}\] and [autodock vina]{.smallcaps} version 1.1.2 \[[12](#feb412875-bib-0012){ref-type="ref"}\]; both interfaces are available in Docking Study with [hyperchem]{.smallcaps} (DSHC) software \[[5](#feb412875-bib-0005){ref-type="ref"}, [13](#feb412875-bib-0013){ref-type="ref"}\], and the resulting docking modes filtered by the [rdock]{.smallcaps} score threshold were more precisely simulated using [autodock vina]{.smallcaps}.

Prior to docking simulations, the inhibitor of the A chain of the M^pro^ homodimer was removed from the system. Then, docking simulations for the 3D structure database (1 485 144 compounds) were performed using the relatively reliable, high‐speed docking simulation program [rdock]{.smallcaps} under the default condition. I expected that the concentrated potential drugs would consist of \~ 70 distinct drugs, the others being bioactive compounds. On the basis of this, I determined the [rdock]{.smallcaps} score threshold to be ≤ −50 kcal·mol^−1^. The cavity condition for [rdock]{.smallcaps} docking simulations was prepared using peptidomimetic α‐ketoamide inhibitor of the A chain under a default condition. Docking simulations output the top three docking modes per trial compound in SDF file format. As a result, 4 455 432 docking modes were obtained. These docking modes were filtered by the [rdock]{.smallcaps} score threshold of ≤ −50 kcal·mol^−1^ to obtain 27 561 distinct compounds (57 649 docking modes) in SDF file format. The ChEMBL IDs of these distinct compounds were subjected to [knime]{.smallcaps} version 4.1.2 \[[14](#feb412875-bib-0014){ref-type="ref"}\] to collect compound information from the ChEMBL web server; some information was manually collected from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database \[[15](#feb412875-bib-0015){ref-type="ref"}\].

From the 57 649 docking modes obtained by virtual screenings, the 27 561 distinct hit compounds had two docking modes on average. The hit compounds, including the 64 drugs I found, could be more precisely investigated using [autodock vina]{.smallcaps} docking simulations with these docking modes as the initial structure. Subsequently, the resulting 57 649 docking modes were separated and converted into individual PDBQT files using DSHC. Then, more precise docking simulations were performed using the [autodock vina]{.smallcaps} *In Silico* Screenings interface integrated into DSHC. The M^pro^ homodimer system prepared above in PDB file format was also converted to a PDBQT file using DSHC. A configuration file with cavity information was prepared using DSHC, and other docking conditions were set to default values (the top nine docking modes per trial compound were maximally outputted). Docking simulations with [autodock vina]{.smallcaps} produced 513 597 docking modes, which were filtered by the [autodock vina]{.smallcaps} score (empirical binding free energy) threshold of −10 kcal·mol^−1^. Since the [autodock vina]{.smallcaps} score is an empirical binding free energy, I expected that −9 kcal·mol^−1^ of a score would theoretically show an nM order of binding affinity with M^pro^. When the threshold for screening was set to less than this value, I obtained 659 distinct compounds (1216 docking modes) as hit compounds. To more realistically concentrate the number of hit compounds, I determined the threshold value to be ≤ −10 kcal·mol^−1^. As a result, I obtained 29 distinct compounds (total 41 docking modes). The ChEMBL IDs of these distinct compounds were subjected to KNIME to collect compound information from the ChEMBL web server.

Results and Discussion {#feb412875-sec-0006}
======================

Structure‐based virtual screenings of the ChEMBL database {#feb412875-sec-0007}
---------------------------------------------------------

In the ChEMBL database, drugs, including approved, clinical, and preclinical drugs, constitute \~ 0.7% of the total number of compounds; the others are mainly bioactive compounds, whose synthesis is, therefore, promising. The advantage for using the ChEMBL database is that it covers all types of drugs, from preclinical to approved stages. I expected that the hit compounds would largely differ from candidates obtained from virtual screenings using focused and targeted libraries \[[16](#feb412875-bib-0016){ref-type="ref"}, [17](#feb412875-bib-0017){ref-type="ref"}\]. With regard to drug repositioning, the ChEMBL database is more suitable for searching for effective known drugs or bioactive compounds when urgent therapy is necessary and effective drugs are not known. The [rdock]{.smallcaps} score threshold of ≤ −50 kcal·mol^−1^ showed relatively high binding affinity with M^pro^.

Table [1](#feb412875-tbl-0001){ref-type="table"} shows the 64 potential drugs that showed high binding affinity with M^pro^, with some drug information collected from the ChEMBL web server using KNIME. I found 11 approved, 14 clinical, and 39 preclinical drugs from the hit compounds (27 561 distinct compounds with 57 649 docking modes); the other 27 497 were bioactive compounds. The 64 drugs were largely classified into antibacterial, antidiabetic, anti‐infective, anti‐inflammatory, antineoplastic, cardiovascular, gastrointestinal, human immunodeficiency virus, and neuropsychiatric drugs. Interestingly, the potential drugs obtained contained sepimostat and curcumin, which are recommended as potential anti‐SARS‐CoV‐2 drugs by researchers \[[18](#feb412875-bib-0018){ref-type="ref"}, [19](#feb412875-bib-0019){ref-type="ref"}\].

###### 

Potential anti‐SARS‐CoV‐2 drugs obtained from [rdock]{.smallcaps} virtual screenings of the ChEMBL database.

  CHEMBL ID       Drug synonym              Stage      Action                              Target                                                    [rdock]{.smallcaps} Score (kcal·mol^−1^)   Vina Score (kcal·mol^−1^)
  --------------- ------------------------- ---------- ----------------------------------- --------------------------------------------------------- ------------------------------------------ ---------------------------
  CHEMBL2105088   LOBENDAZOLE                          Anthelmintic                                                                                  −52.1429                                   −6.5
  CHEMBL2105653   SETILEUTON                           Antiasthmatic                       5‐Lipoxygenase inhibitor                                  −60.4636                                   −8.3
  CHEMBL1191      SULFAMETHIZOLE            Approved   Antibacterial                       Dihydropteroate synthase inhibitor                        −79.7939                                   −6.6
  CHEMBL437       SULFATHIAZOLE             Approved   Antibacterial                       Dihydropteroate synthase inhibitor                        −72.0537                                   −6.5
  CHEMBL1384      KANAMYCIN                 Approved   Antibacterial                       30S ribosomal subunit inhibitor                           −71.2391                                   −7.5
  CHEMBL1747      TOBRAMYCIN                Approved   Antibacterial                       50S ribosomal subunit inhibitor                           −56.0916                                   −6.6
  CHEMBL1524273   PHTHALYLSULFATHIAZOLE     Approved   Antibacterial                       Cytochrome P450 3A4, dihydropteroate synthase inhibitor   −51.7695                                   −7.3
  CHEMBL2105399   SULFAMOXOLE                          Antibacterial                       Dihydropteroate synthase inhibitor                        −87.8995                                   −7.2
  CHEMBL1355299   SULFAETHIDOLE                        Antibacterial                       Putative fructose‐1,6‐bisphosphate aldolase               −84.7512                                   −7.0
  CHEMBL2105398   SULFAMETROLE                         Antibacterial                                                                                 −69.6628                                   −6.6
  CHEMBL2105403   PENTISOMICIN                         Antibacterial                                                                                 −59.2134                                   −7.3
  CHEMBL2110604   BETAMICIN                            Antibacterial                                                                                 −54.6510                                   −7.7
  CHEMBL2107073   SANFETRINEM CILEXETIL                Antibacterial                                                                                 −52.6940                                   −7.8
  CHEMBL94087     GLYBUTHIAZOL                         Antidiabetic                                                                                  −83.8342                                   −6.8
  CHEMBL490070    BENAXIBINE                           Antidiabetic                        Monoamine oxidase A                                       −52.5382                                   −6.9
  CHEMBL2107408   GLYBUZOLE                            Antidiabetic, Anti‐Hyperglycemic,                                                             −73.5918                                   −6.6
  CHEMBL2104694   ACEFLURANOL                          Antiestrogen                                                                                  −57.3375                                   −7.4
  CHEMBL1950289   TANZISERTIB               Phase2     Antifibrotic                        c‐Jun N‐terminal kinase inhibitor                         −60.6067                                   −8.5
  CHEMBL2107669   VIPROSTOL                            Antihypertensive                    Prostaglandin analogue                                    −52.3341                                   −6.5
  CHEMBL2106914   PHTHALYLSULFAMETHIZOLE               Anti‐infective                                                                                −84.7500                                   −7.9
  CHEMBL2106807   MALEYLSULFATHIAZOLE                  Anti‐infective                                                                                −66.6682                                   −7.0
  CHEMBL157337    RAMIFENAZONE                         Anti‐Inflammatory                   Adrenergic receptor beta                                  −79.4409                                   −6.3
  CHEMBL2104561   ELTENAC                              Anti‐Inflammatory                   COX2                                                      −72.5029                                   −6.1
  CHEMBL114586    SEPIMOSTAT                           Anti‐Inflammatory                   Serine protease inhibitor                                 −58.1205                                   −7.9
  CHEMBL2110642   DIBUPYRONE                           Anti‐Inflammatory                                                                             −57.8675                                   −6.1
  CHEMBL2104226   ETERSALATE                           Anti‐Inflammatory                                                                             −53.3912                                   −7.0
  CHEMBL2058833   GANAPLACIDE               Phase2     Antimalarial                                                                                  −70.6688                                   −7.7
  CHEMBL2396661   ALPELISIB                 Approved   Antineoplastic                      Serine‐protein kinase ATM                                 −67.1970                                   −8.3
  CHEMBL25336     BISANTRENE                Phase3     Antineoplastic                                                                                −54.2373                                   −8.5
  CHEMBL2103842   VARLITINIB                Phase2     Antineoplastic                      EGFR‐HER2 inhibitor                                       −69.1763                                   −8.1
  CHEMBL2180604   TAK‐593                   Phase1     Antineoplastic                      Vascular endothelial growth factor receptor 3             −65.4614                                   −8.1
  CHEMBL3182444   MK‐5108                   Phase1     Antineoplastic                      Aurora‐A kinase inhibitor                                 −52.9359                                   −6.7
  CHEMBL1079      TIZANIDINE                Approved   Cardiovascular                      Adrenergic receptor alpha agonist                         −78.7516                                   −6.3
  CHEMBL259223    MENATETRENONE             Phase3     Cardiovascular                      Vitamin K‐dependent gamma‐carboxylase                     −75.9905                                   −6.3
  CHEMBL321582    BUCINDOLOL                Phase2     Cardiovascular                      Adrenergic receptor beta antagonist                       −50.6285                                   −7.0
  CHEMBL12552     BIMAKALIM                            Cardiovascular                      Potassium channel opener                                  −67.8339                                   −7.1
  CHEMBL2106134   DALBRAMINOL                          Cardiovascular                      Beta blocker                                              −67.3284                                   −6.3
  CHEMBL358373    INDANIDINE                           Cardiovascular                      Adrenergic receptor alpha agonist                         −66.5682                                   −6.2
  CHEMBL297362    XYLAZINE                             Cardiovascular                      Adrenergic receptor alpha agonist                         −53.0909                                   −5.7
  CHEMBL689       MANNITOL                  Approved   Gastrointestinal                                                                              −51.6980                                   −5.3
  CHEMBL70209     ZALTIDINE                            Gastrointestinal                    Histamine receptor H2 antagonist                          −57.8372                                   −6.3
  CHEMBL1742413   PIBUTIDINE                           Gastrointestinal                    Histamine 2 receptor antagonist                           −53.1955                                   −7.7
  CHEMBL116438    CURCUMIN                  Phase3     HIV                                 HIV‐1 integrase                                           −55.7724                                   −7.3
  CHEMBL2360841   RO‐24‐7429                Phase2     HIV                                 Tyrosyl‐DNA phosphodiesterase 1                           −58.6922                                   −6.7
  CHEMBL2105488   THYMOTRINAN                          Immunostimulant                                                                               −50.6933                                   −7.1
  CHEMBL593262    PARA‐NITROSULFATHIAZOLE              Leishmania Infantum                                                                           −80.0130                                   −7.0
  CHEMBL2107425   GLUCUROLACTONE                       Liver function improving                                                                      −50.5937                                   −5.8
  CHEMBL1108      DROPERIDOL                Approved   Neuropsychiatric                    Dopamine D2‐receptor antagonist                           −59.2556                                   −7.5
  CHEMBL1522      ESZOPICLONE               Approved   Neuropsychiatric                    GABA‐A receptor agonist                                   −54.5048                                   −10.0
  CHEMBL1618018   HOMATROPINE               Approved   Neuropsychiatric                    Muscarinic cholinergic receptor antagonist                −50.4433                                   −6.7
  CHEMBL1394756   ESOXYBUTYNIN                         Neuropsychiatric                    NF‐Kappa‐B, muscarinic cholinergic receptor antagonist    −51.7716                                   −5.9
  CHEMBL2110912   DIHEXYVERINE                         Neuropsychiatric                    Muscarinic cholinergic receptor antagonist                −51.2083                                   −6.8
  CHEMBL55214     NERIDRONIC ACID           Phase3     Osteogenesis Imperfecta                                                                       −52.9425                                   −5.6
  CHEMBL2106834   METOXEPIN                            Psychotropic                                                                                  −53.3412                                   −7.4
  CHEMBL1231124   AZD‐1480                  Phase2                                         Tyrosine‐protein kinase JAK2 inhibitor                    −56.3449                                   −8.0
  CHEMBL10188     TALNETANT                 Phase2                                         Neurokinin 3 receptor antagonist                          −52.4637                                   −7.7
  CHEMBL563646    EVATANEPAG                Phase2                                         Prostanoid EP2 receptor                                   −50.5628                                   −8.0
  CHEMBL2105528   BISFENAZONE                                                              Carboxylesterase                                          −66.3130                                   −7.9
  CHEMBL2105110   LAMTIDINE                                                                Histamine 2 receptor antagonist                           −65.9473                                   −6.9
  CHEMBL67654     CAREBASTINE                                                              Histamine H1 receptor antagonist                          −55.9690                                   −7.7
  CHEMBL155674    ASOBAMAST                                                                TNF receptor 2                                            −52.7795                                   −7.1
  CHEMBL1603949   BITHIONOLOXIDE                                                           Menin/histone‐lysine *N*‐methyltransferase MLL            −52.4736                                   −6.9
  CHEMBL2105536   SULFACECOLE                                                                                                                        −52.0995                                   −7.0
  CHEMBL2104446   VANYLDISULFAMIDE                                                                                                                   −50.1930                                   −8.3
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Additional docking simulations for hit compounds {#feb412875-sec-0008}
------------------------------------------------

Table [2](#feb412875-tbl-0002){ref-type="table"} shows the 29 hit compounds obtained using [autodock vina]{.smallcaps} virtual screenings with ≤ −10 kcal·mol^−1^ of binding free energy for M^pro^. For the 64 drugs, [autodock vina]{.smallcaps} scores of the most stable docking modes are also shown in Table [1](#feb412875-tbl-0001){ref-type="table"}.

###### 

Hit compounds obtained by combining [autodock vina]{.smallcaps} and [rdock]{.smallcaps} virtual screenings of the ChEMBL database.

  CHEMBL ID       Structure                           Target                                     Vina score (kcal·mol^−1^)
  --------------- ----------------------------------- ------------------------------------------ ---------------------------
  CHEMBL1559003   ![](FEB4-10-995-g003.jpg "image")   Survival motor neuron protein              −10.6
  CHEMBL2237553   ![](FEB4-10-995-g004.jpg "image")   *Aspergillus niger*                        −10.5
  CHEMBL1511674   ![](FEB4-10-995-g005.jpg "image")   Histone‐lysine *N*‐methyltransferase MLL   −10.5
  CHEMBL3260476   ![](FEB4-10-995-g006.jpg "image")   Heat shock protein HSP 90‐alpha            −10.4
  CHEMBL1170272   ![](FEB4-10-995-g007.jpg "image")   Serotonin 6(5‐HT6) receptor                −10.4
  CHEMBL1335000   ![](FEB4-10-995-g008.jpg "image")                                              −10.4
  CHEMBL2235580   ![](FEB4-10-995-g009.jpg "image")   *Mus musculus*                             −10.3
  CHEMBL3264032   ![](FEB4-10-995-g010.jpg "image")   *Staphylococcus aureus*                    −10.3
  CHEMBL1447105   ![](FEB4-10-995-g011.jpg "image")   4′‐phosphopantetheinyl transferase FFP     −10.2
  CHEMBL589899    ![](FEB4-10-995-g012.jpg "image")   Bradykinin B1 receptor                     −10.2
  CHEMBL1539803   ![](FEB4-10-995-g013.jpg "image")   Lysine‐specific demethylase 4D‐like        −10.2
  CHEMBL2216842   ![](FEB4-10-995-g014.jpg "image")   PI3‐kinase p110‐delta subunit              −10.2
  CHEMBL427787    ![](FEB4-10-995-g015.jpg "image")   Serine threonine‐protein kinase aurora‐A   −10.2
  CHEMBL1339675   ![](FEB4-10-995-g016.jpg "image")                                              −10.2
  CHEMBL3126648   ![](FEB4-10-995-g017.jpg "image")   DNA(Cytosine‐5)‐methyltransferase 1        −10.1
  CHEMBL1302388   ![](FEB4-10-995-g018.jpg "image")   Prelamin‐A/C                               −10.1
  CHEMBL3234783   ![](FEB4-10-995-g019.jpg "image")   *Staphylococcus aureus*                    −10.1
  CHEMBL1807774   ![](FEB4-10-995-g020.jpg "image")   Tyrosine‐protein kinase receptor RET       −10.1
  CHEMBL2087984   ![](FEB4-10-995-g021.jpg "image")                                              −10.1
  CHEMBL2387487   ![](FEB4-10-995-g022.jpg "image")   ACHN                                       −10.0
  CHEMBL2113271   ![](FEB4-10-995-g023.jpg "image")   Adenosine A1 receptor                      −10.0
  CHEMBL476947    ![](FEB4-10-995-g024.jpg "image")   Cannabinoid CB2 receptor                   −10.0
  CHEMBL399042    ![](FEB4-10-995-g025.jpg "image")   Cyclin‐dependent kinase 1                  −10.0
  CHEMBL2000247   ![](FEB4-10-995-g026.jpg "image")   Integrase                                  −10.0
  CHEMBL3236740   ![](FEB4-10-995-g027.jpg "image")   *Mus musculus*                             −10.0
  CHEMBL1447944   ![](FEB4-10-995-g028.jpg "image")   Nonstructural protein 1                    −10.0
  CHEMBL1760165   ![](FEB4-10-995-g029.jpg "image")   Serine threonine‐protein kinase mTOR       −10.0
  CHEMBL2087965   ![](FEB4-10-995-g030.jpg "image")                                              −10.0
  CHEMBL1522      ![](FEB4-10-995-g031.jpg "image")   GABA‐A receptor agonist                    −10.0
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Almost all the 29 hit compounds were bioactive compounds registered to the ChEMBL database, except for eszopiclone (CHEMBL1522; approved drug for neuropsychiatric disease). I believe that these hit compounds were not developed for common targets, although the structural feature could be categorized into some mother skeletons, such as diazole, azine, and sulfone derivatives (Table [2](#feb412875-tbl-0002){ref-type="table"}).

Figure [2](#feb412875-fig-0002){ref-type="fig"} shows the most stable docking modes of sepimostat (Fig. [2B](#feb412875-fig-0002){ref-type="fig"}; [autodock vina]{.smallcaps} score −7.9 kcal·mol^−1^), curcumin (Fig. [2C](#feb412875-fig-0002){ref-type="fig"}; [autodock vina]{.smallcaps} score −7.3 kcal·mol^−1^), and eszopiclone (Fig. [2D](#feb412875-fig-0002){ref-type="fig"}; [autodock vina]{.smallcaps} score −10.0 kcal·mol^−1^) obtained from [autodock vina]{.smallcaps} docking simulations, in addition to the binding mode of peptidomimetic α‐ketoamide inhibitor in the crystal structure (Fig. [2A](#feb412875-fig-0002){ref-type="fig"}). Researchers consider sepimostat, curcumin, and the α‐ketoamide inhibitor to be potential anti‐SARS‐CoV‐2 drugs. In this study, eszopiclone was also the only approved drug with the highest score on [autodock vina]{.smallcaps} docking simulations (Tables [1](#feb412875-tbl-0001){ref-type="table"} and [2](#feb412875-tbl-0002){ref-type="table"}). The carbonyl moiety of these compounds was close to the catalytic site of the Cys145 and His41 catalytic dyad, and docking modes were similar to each other. These results suggest that these compounds may function through the same underlying mechanism.

![The most stable docking mode obtained from [autodock vina]{.smallcaps} docking simulations. (A) Binding mode of peptidomimetic α‐ketoamide inhibitor in the crystal structure. (B) Sepimostat, (C) curcumin, and (D) eszopiclone. Chains A and B of the M^pro^ homodimer are shown as red and cyan ribbons, respectively. The compound, Cys145, and His41 are shown as tubes. Van der Waals surface of the active site is shown in gray color. Water molecules and hydrogen atoms are neglected.](FEB4-10-995-g002){#feb412875-fig-0002}

Conclusions {#feb412875-sec-0009}
===========

This study was performed to rapidly identify potential anti‐SARS‐CoV‐2 drug candidates from a known drug library on the basis of drug repositioning. The drug candidates presented in this study could be further examined for their anti‐SARS‐CoV‐2 activities, together with those of earlier studies using more limited drug libraries \[[20](#feb412875-bib-0020){ref-type="ref"}, [21](#feb412875-bib-0021){ref-type="ref"}, [22](#feb412875-bib-0022){ref-type="ref"}\]. Bioactive compounds with high binding affinity for SARS‐CoV‐2 M^pro^ could be used as a basis for improving pharmacokinetic properties and for developing specific anti‐SARS‐CoV‐2 drugs. Combinations of structure‐based docking simulations are valuable for high‐throughput virtual screenings to identify urgently needed therapies for viral infections. Determination of the effect of potential anti‐SARS‐CoV‐2 drugs obtained in this study is in progress, and the results will be published in the near future.
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